ArticleMolecular oncology2026

Proteasome inhibitor, ixazomib prevents topoisomerase-I degradation and reverses irinotecan resistance in colorectal cancer.

Yuho Ebata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.